Availability for Non-Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Antibodies Against Type A Botulinum Neurotoxin

---
identifier: "/us/fr/02-13045"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Availability for Non-Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Antibodies Against Type A Botulinum Neurotoxin"
title_number: 0
title_name: "Federal Register"
section_number: "02-13045"
section_name: "Availability for Non-Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Antibodies Against Type A Botulinum Neurotoxin"
positive_law: false
currency: "2002-05-24"
last_updated: "2002-05-24"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Defense Department"
document_number: "02-13045"
document_type: "notice"
publication_date: "2002-05-24"
agencies:
  - "Defense Department"
  - "Army Department"
fr_citation: "67 FR 36577"
fr_volume: 67
fr_action: "Notice."
---


#  Availability for Non-Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Antibodies Against Type A Botulinum Neurotoxin

**AGENCY:**

Department of the Army, DOD

**ACTION:**

Notice.

**SUMMARY:**

In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent Application No. 09/465,276 entitled “Antibodies Against Type A Botulinum Neurotoxin,” filed December 16, 1999. The United States Government, as represented by the Secretary of the Army has rights in this invention.

**ADDRESSES:**

Commander, U.S. army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick Frederick, MD 21702-5012.

**FOR FURTHER INFORMATION CONTACT:**

For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.

**SUPPLEMENTARY INFORMATION:**

Antibodies for binding epitopes of BoNT/A and hybridomas which produce such antibodies are described. The antibodies of the present invention can be used in a method for detecting BoNT/A in a sample and/or in a method for purifying BoNT/A from an impure solution. In addition, the antibodies can to be used for passive immunization against BoNT/A intoxication or as intoxication therapy. Another aspect of the invention is a kit for detecting BoNT/A in a sample.

Luz D. Ortiz,

Army Federal Register Liaison Officer.